MedTrace Logo

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

NCT01418222 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 194

Last updated 2017-05-30

No results posted yet for this study

Summary

This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of FOLFOX/bevacizumab with onartuzumab (MetMAb) versus placebo as first-line treatment in patients with metastatic colorectal cancer.

Conditions

Interventions

DRUG

5-FU

Intravenous repeating dose

DRUG

FOLFOX regimen

Intravenous repeating dose

DRUG

Placebo

Intravenous repeating dose

DRUG

bevacizumab [Avastin]

Intravenous repeating dose

DRUG

leucovorin

Intravenous repeating dose

DRUG

onartuzumab [MetMAb]

Intravenous repeating dose

Sponsors & Collaborators

  • SCRI Development Innovations, LLC

    collaborator OTHER

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Genentech, Inc.

Study Design

Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-14
Primary Completion
2013-03-18
Completion
2013-03-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01418222 on ClinicalTrials.gov